The Orphan Drug Act was needed not only to provide financial incentives to companies but also to allow drugmakers more leeway in designing studies to prove that a drug candidate is safe and effective.

• 孤儿药法案不仅为厂商提供经济诱因，也为制药商在设计实验证明药物的安全性与疗效时，提供了更多的空间。